Current Report Filing (8-k)
26 September 2018 - 2:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event
reported): September 26, 2018
RXi PHARMACEUTICALS CORPORATION
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36304
|
|
45-3215903
|
(State
or other jurisdiction of
incorporation
or organization)
|
|
(Commission
File
Number)
|
|
(I.R.S.
Employer
Identification No.)
|
257 Simarano Drive, Suite 101
Marlborough, Massachusetts 01752
(Address
of Principal Executive Offices) (Zip Code)
Registrant’s telephone number,
including area code: (508) 767-3861
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 7.01
|
Regulation FD Disclosure
.
|
On September 26, 2018, representatives of
RXi Pharmaceuticals Corporation participated in the 16
th
Annual Discovery on Target
Conference in Boston, Massachusetts. A copy of the poster to be used during the conference is attached hereto as Exhibit
99.1 and is incorporated herein by reference.
The information
in this Item 7.01 and attached as Exhibit 99.1 to this Current Report on Form 8-K will not be treated as “filed” for
the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities
Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information
by reference.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
99.1 Conference Poster, dated
September 26, 2018.
* * *
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
RXi PHARMACEUTICALS CORPORATION
|
|
|
|
|
|
|
|
|
Date: September 26, 2018
|
|
|
|
By:
|
|
/s/ Geert Cauwenbergh
|
|
|
|
|
|
|
|
|
Geert Cauwenbergh, Dr. Med. Sc.
Chief Executive Officer
|
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Rxi Pharmaceuticals Corp. (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Rxi Pharmaceuticals Corp News-Artikel